Sawai Moves Ahead In Japan, But Is Dragged Down By US
Receives Eight Japanese Approvals, Including Five First Generics
Sawai has overcome obstacles in its home market to register growth in Japan in the first nine months of its current financial year. However, the firm has seen its overall sales and profits dragged down by a slump in the US.
You may also be interested in...
Sawai was strong in Japan and weak in the US in the first financial quarter of its 2022 financial year, as analysts called on the Japanese firm to improve supply capacity as a “crucial first step towards expanding market share.”
Sawai Pharmaceutical has major plans for its US business that include consolidating its manufacturing operations at a single site and bolstering its pipeline and portfolio, Sawai president Kenzo Sawai tells Generics Bulletin in an exclusive interview.
In the face of both local and global pressures, Japan’s Sawai Pharmaceutical is holding steady by relying on its core strengths, company president Kenzo Sawai tells Generics Bulletin in the first part of an exclusive two-part interview.